Terms: = Ovarian cancer AND CDK4, PSK-J3, 1019, ENSG00000135446, MGC14458, CMM3, P11802 AND Prognosis
20 results:
1. ER-positive and BRCA2-mutated breast cancer: a literature review.
Li PC; Zhu YF; Cao WM; Li B
Eur J Med Res; 2024 Jan; 29(1):30. PubMed ID: 38184581
[TBL] [Abstract] [Full Text] [Related]
2. [Arguments for centralization of surgical treatment of ovarian cancer in France based on morbidity and mortality data].
Meurette J; Daraï E; Tajahmady A; Fouard A; Ducastel A; Collin-Bund V; Jochum F; Lecointre L; Querleu D; Akladios C
Bull Cancer; 2024 Mar; 111(3):239-247. PubMed ID: 36797128
[TBL] [Abstract] [Full Text] [Related]
3. Targeting the FGF/FGFR axis and its co-alteration allies.
Uehara Y; Ikeda S; Kim KH; Lim HJ; Adashek JJ; Persha HE; Okamura R; Lee S; Sicklick JK; Kato S; Kurzrock R
ESMO Open; 2022 Dec; 7(6):100647. PubMed ID: 36455506
[TBL] [Abstract] [Full Text] [Related]
4. The Immunological Role of cdk4/6 and Potential Mechanism Exploration in ovarian cancer.
Liu C; Huang Y; Cui Y; Zhou J; Qin X; Zhang L; Li X; Li Y; Guo E; Yang B; Li X; Fan J; Li X; Fu Y; Liu S; Hu D; Xiao R; Wang Z; Dou Y; Wang W; Li W; Yang X; Liu J; Peng W; Qin T; You L; Lu F; Sun C
Front Immunol; 2021; 12():799171. PubMed ID: 35095879
[TBL] [Abstract] [Full Text] [Related]
5. lncRNA TPT1‑AS1 knockdown inhibits liver cancer cell proliferation, migration and invasion.
Li H; Jin J; Xian J; Wang W
Mol Med Rep; 2021 Nov; 24(5):. PubMed ID: 34498708
[TBL] [Abstract] [Full Text] [Related]
6. A first-in-class cdk4 inhibitor demonstrates in vitro, ex-vivo and in vivo efficacy against ovarian cancer.
Bantie L; Tadesse S; Likisa J; Yu M; Noll B; Heinemann G; Lokman NA; Ricciardelli C; Oehler MK; Beck A; Pradhan R; Milne R; Albrecht H; Wang S
Gynecol Oncol; 2020 Dec; 159(3):827-838. PubMed ID: 32958271
[TBL] [Abstract] [Full Text] [Related]
7. Knockdown of ribosomal protein S6 suppresses proliferation, migration, and invasion in epithelial ovarian cancer.
Yang X; Xu L; Yang YE; Xiong C; Yu J; Wang Y; Lin Y
J Ovarian Res; 2020 Aug; 13(1):100. PubMed ID: 32862831
[TBL] [Abstract] [Full Text] [Related]
8. Hsa_circ_0009910: oncogenic circular RNA targets microRNA-145 in ovarian cancer cells.
Li Y; Lin S; An N
Cell Cycle; 2020 Aug; 19(15):1857-1868. PubMed ID: 32588730
[TBL] [Abstract] [Full Text] [Related]
9. Clinical Characteristics and Mutation Analyses of ovarian Sertoli-Leydig Cell Tumors.
Yuan Z; Huo X; Jiang D; Yu M; Cao D; Wu H; Shen K; Yang J; Zhang Y; Zhou H; Wang Y
Oncologist; 2020 Sep; 25(9):e1396-e1405. PubMed ID: 32557933
[TBL] [Abstract] [Full Text] [Related]
10. HP-CagA+ Regulates the Expression of cdk4/CyclinD1 via
Liu B; Li X; Sun F; Tong X; Bai Y; Jin K; Liu L; Dai F; Li N
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31905669
[TBL] [Abstract] [Full Text] [Related]
11. LINC00968 accelerates the progression of epithelial ovarian cancer via mediating the cell cycle progression.
Yao N; Sun JQ; Yu L; Ma L; Guo BQ
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(11):4642-4649. PubMed ID: 31210289
[TBL] [Abstract] [Full Text] [Related]
12. Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an ovarian Tumor Tissue Analysis consortium study.
Rambau PF; Vierkant RA; Intermaggio MP; Kelemen LE; Goodman MT; Herpel E; Pharoah PD; Kommoss S; Jimenez-Linan M; Karlan BY; Gentry-Maharaj A; Menon U; Polo SH; Candido Dos Reis FJ; Doherty JA; Gayther SA; Sharma R; Larson MC; Harnett PR; Hatfield E; de Andrade JM; Nelson GS; Steed H; Schildkraut JM; Carney ME; Høgdall E; Whittemore AS; Widschwendter M; Kennedy CJ; Wang F; Wang Q; Wang C; Armasu SM; Daley F; Coulson P; Jones ME; Anglesio MS; Chow C; de Fazio A; García-Closas M; Brucker SY; Cybulski C; Harris HR; Hartkopf AD; Huzarski T; Jensen A; Lubiński J; Oszurek O; Benitez J; Mina F; Staebler A; Taran FA; Pasternak J; Talhouk A; Rossing MA; Hendley J; ; Edwards RP; Fereday S; Modugno F; Ness RB; Sieh W; El-Bahrawy MA; Winham SJ; Lester J; Kjaer SK; Gronwald J; Sinn P; Fasching PA; Chang-Claude J; Moysich KB; Bowtell DD; Hernandez BY; Luk H; Behrens S; Shah M; Jung A; Ghatage P; Alsop J; Alsop K; García-Donas J; Thompson PJ; Swerdlow AJ; Karpinskyj C; Cazorla-Jiménez A; García MJ; Deen S; Wilkens LR; Palacios J; Berchuck A; Koziak JM; Brenton JD; Cook LS; Goode EL; Huntsman DG; Ramus SJ; Köbel M
J Pathol Clin Res; 2018 Oct; 4(4):250-261. PubMed ID: 30062862
[TBL] [Abstract] [Full Text] [Related]
13. Targeted Therapy for Premenopausal Women with HR
Bardia A; Hurvitz S
Clin Cancer Res; 2018 Nov; 24(21):5206-5218. PubMed ID: 29884743
[TBL] [Abstract] [Full Text] [Related]
14. Prognostic importance of cdk4/6-specific activity as a predictive marker for recurrence in patients with endometrial cancer, with or without adjuvant chemotherapy.
Ikeda Y; Oda K; Ishihara H; Wada-Hiraike O; Miyasaka A; Kashiyama T; Inaba K; Fukuda T; Sone K; Matsumoto Y; Arimoto T; Maeda D; Ikemura M; Fukayama M; Kawana K; Yano T; Aoki D; Osuga Y; Fujii T
Br J Cancer; 2015 Nov; 113(10):1477-83. PubMed ID: 26554657
[TBL] [Abstract] [Full Text] [Related]
15. CXCR2 promotes ovarian cancer growth through dysregulated cell cycle, diminished apoptosis, and enhanced angiogenesis.
Yang G; Rosen DG; Liu G; Yang F; Guo X; Xiao X; Xue F; Mercado-Uribe I; Huang J; Lin SH; Mills GB; Liu J
Clin Cancer Res; 2010 Aug; 16(15):3875-86. PubMed ID: 20505188
[TBL] [Abstract] [Full Text] [Related]
16. The role of KLF6 and its splice variants in cancer therapy.
DiFeo A; Martignetti JA; Narla G
Drug Resist Updat; 2009; 12(1-2):1-7. PubMed ID: 19097929
[TBL] [Abstract] [Full Text] [Related]
17. Effects of common germ-line genetic variation in cell cycle genes on ovarian cancer survival.
Song H; Hogdall E; Ramus SJ; Dicioccio RA; Hogdall C; Quaye L; McGuire V; Whittemore AS; Shah M; Greenberg D; Easton DF; Kjaer SK; Pharoah PD; Gayther SA
Clin Cancer Res; 2008 Feb; 14(4):1090-5. PubMed ID: 18281541
[TBL] [Abstract] [Full Text] [Related]
18. Alteration of cell cycle regulators correlates with survival in epithelial ovarian cancer patients.
Hashiguchi Y; Tsuda H; Inoue T; Nishimura S; Suzuki T; Kawamura N
Hum Pathol; 2004 Feb; 35(2):165-75. PubMed ID: 14991533
[TBL] [Abstract] [Full Text] [Related]
19. Inverse expression of cdk4 and p16 in epithelial ovarian tumors.
Sui L; Dong Y; Ohno M; Goto M; Inohara T; Sugimoto K; Tai Y; Hando T; Tokuda M
Gynecol Oncol; 2000 Nov; 79(2):230-7. PubMed ID: 11063650
[TBL] [Abstract] [Full Text] [Related]
20. Sporadic CDKN2 (MTS1/p16ink4) gene alterations in human ovarian tumours.
Schuyer M; van Staveren IL; Klijn JG; vd Burg ME; Stoter G; Henzen-Logmans SC; Foekens JA; Berns EM
Br J Cancer; 1996 Oct; 74(7):1069-73. PubMed ID: 8855976
[TBL] [Abstract] [Full Text] [Related]
